Privium Fund Management B.V. Purchases 15,409 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Privium Fund Management B.V. raised its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 125.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 27,709 shares of the company’s stock after purchasing an additional 15,409 shares during the period. Privium Fund Management B.V.’s holdings in Intellia Therapeutics were worth $323,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NTLA. Whipplewood Advisors LLC bought a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $40,000. KBC Group NV increased its stake in Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after buying an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after acquiring an additional 2,299 shares during the period. Finally, Point72 DIFC Ltd purchased a new position in shares of Intellia Therapeutics in the third quarter valued at about $151,000. 88.77% of the stock is currently owned by institutional investors.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

NTLA has been the subject of several research analyst reports. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Barclays lowered their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Citigroup raised their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Finally, HC Wainwright started coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $9.19 on Wednesday. The company has a market cap of $951.32 million, a PE ratio of -1.69 and a beta of 1.97. Intellia Therapeutics, Inc. has a 1 year low of $8.30 and a 1 year high of $28.54. The stock’s 50 day simple moving average is $10.23 and its two-hundred day simple moving average is $14.40.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.